The global lateral flow assays market was valued at USD 10.2 billion in 2025 and is estimated to reach USD 10.6 billion in 2026. According to Grand View Research, the market is projected to reach USD 17.4 billion by 2033, expanding at a CAGR of 7.4% from 2026 to 2033. The market is benefiting from the growing need for rapid, affordable, and accessible diagnostic solutions, particularly across point-of-care (POC), clinical, and home-testing environments. The increasing prevalence of infectious diseases and continued advances in diagnostic technologies are further strengthening demand for lateral flow assays worldwide.

Market Segmentation Highlights

The lateral flow assays industry is supported by a broad range of products and applications spanning clinical diagnostics, veterinary testing, food safety, environmental monitoring, and drug development.

• By Product: Kits and reagents dominated the market with a 66.6% revenue share in 2025. Their strong position reflects the widespread use of disposable lateral flow tests and the recurring demand generated by rapid diagnostic testing. Lateral flow readers represent another important product category and include digital/mobile readers and benchtop readers. Digital and mobile readers are gaining attention as healthcare providers increasingly seek more accurate and connected interpretation of test results.

• By Application: Clinical testing held the leading position, accounting for 74.2% of revenue in 2025. Lateral flow assays are widely used for infectious disease testing, including COVID-19, malaria, dengue, influenza, HIV, hepatitis, tuberculosis, and other conditions. Other applications include cardiac marker testing, pregnancy and fertility testing, cholesterol and lipid profile testing, drugs-of-abuse testing, veterinary diagnostics, food safety and environment testing, and drug development and quality testing.

• By Technique: Sandwich assays represented the largest technique segment, accounting for 38.6% of revenue in 2025. Their accuracy, cost-effectiveness, and ease of use make them particularly valuable in settings where rapid diagnostic results are required. Meanwhile, multiplex detection assays are expected to experience strong growth because they can identify multiple targets from a single sample, helping reduce testing time and sample requirements.

• By End Use: Hospitals and clinics accounted for 34.9% of revenue in 2025, making them the leading end-use segment. These healthcare facilities rely on LFAs for rapid disease screening, diagnosis, and patient management. At the same time, home care is becoming increasingly important as consumers seek convenient testing solutions that can provide results without requiring a visit to a healthcare facility. Diagnostic laboratories are also expected to witness significant expansion during the forecast period.

Download a free sample copy of the Lateral Flow Assays Market report to understand detailed coverage and inclusions in the final report

Key Growth Drivers and Emerging Trends

Rising Demand for Point-of-Care Diagnostics

The shift toward decentralized healthcare is one of the major factors supporting the expansion of lateral flow assays. POC tests allow healthcare professionals and patients to obtain diagnostic information quickly without relying entirely on centralized laboratories. Their relatively simple operation, affordability, and portability make them suitable for hospitals, clinics, pharmacies, community settings, and households.

The growing burden of infectious diseases is further reinforcing this trend. Rapid testing has become increasingly important for identifying diseases at an early stage and supporting timely treatment decisions.

Digitalization and Smart Lateral Flow Readers

Technology is transforming conventional lateral flow tests from simple visual diagnostic strips into increasingly connected diagnostic platforms. Smartphone-compatible readers and digital/mobile devices can improve result interpretation and support more consistent testing. Grand View Research highlights advances in smartphone applications, cloud-connected devices, signal amplification, and multiplexing as important technological developments shaping the industry.

Digital technologies can also expand the usefulness of LFAs beyond basic qualitative results. As connected testing becomes more sophisticated, manufacturers can address demand for improved accuracy, quantitative analysis, data management, and integration with broader healthcare workflows.

Expansion of Multiplex and Nucleic Acid Testing

Innovation in assay techniques is creating opportunities for higher-performance diagnostic products. Multiplex detection enables several targets to be analyzed within a single test, making the approach valuable for infectious disease diagnostics as well as food and feed testing.

Nucleic acid lateral flow assays are also emerging as an important technology area. These tests focus on detecting amplified nucleic-acid targets and have the potential to complement traditional antibody-based lateral flow immunoassays. Advances in DNA amplification, CRISPR-based technologies, nanoparticles, and signal-enhancement techniques could further improve the sensitivity and capabilities of next-generation LFAs.

Regional Market Insights

North America maintained its position as the largest regional market, accounting for a 35.4% revenue share in 2025. Strong healthcare infrastructure, widespread availability of rapid diagnostic technologies, government support for healthcare research, and demand for infectious disease testing continue to support regional growth. The U.S. accounted for the largest revenue share within North America in 2025.

Europe is also witnessing steady expansion, supported by government initiatives, investment in rapid diagnostics, regulatory developments, and collaborations among healthcare and technology companies. The UK, Germany, France, Italy, Spain, Sweden, Denmark, and Norway are among the countries covered in Grand View Research's analysis.

Meanwhile, Asia Pacific presents substantial long-term opportunities due to its large population base, increasing healthcare expenditure, rising disposable incomes, and growing adoption of POC diagnostics. Countries including China, Japan, India, South Korea, Australia, and Thailand are contributing to the region's expanding diagnostic ecosystem. The high prevalence of infectious diseases such as tuberculosis and dengue is also creating demand for affordable and accessible testing solutions.

Looking for more specific insights? Customize this report to suite your business needs

Competitive Landscape and Key Players

The competitive environment is characterized by continuous product development, technological innovation, strategic partnerships, acquisitions, and geographic expansion. Companies are focusing on improving sensitivity and specificity while developing convenient formats for clinical, POC, laboratory, and home-testing applications.

Grand View Research identifies Abbott, Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche AG, Bio-Rad Laboratories, Inc., bioMérieux SA, Quidel Corporation, Hologic, Inc., QIAGEN, DH Life Sciences, LLC., and Siemens Healthineers among the key companies operating in the industry.

Recent strategic activity demonstrates the industry's focus on strengthening POC capabilities. In January 2025, bioMérieux announced an agreement to acquire SpinChip Diagnostics ASA, a Norwegian diagnostics company specializing in immunoassay platforms. Such developments highlight how established diagnostic companies are using acquisitions and partnerships to expand technological capabilities and strengthen their positions in rapid diagnostics.

Outlook for the Lateral Flow Assays Industry

The future of the lateral flow assays industry is being shaped by the convergence of rapid diagnostics, decentralized healthcare, digital connectivity, and advanced biotechnology. From infectious disease screening and pregnancy testing to food safety, veterinary diagnostics, and drug development, the applications of LFA technology continue to broaden.

With the global market expected to increase from USD 10.6 billion in 2026 to USD 17.4 billion by 2033, the industry is positioned for sustained expansion. A 7.4% CAGR from 2026 to 2033 reflects the growing importance of rapid, accessible, and cost-effective diagnostic technologies. As manufacturers continue investing in multiplex testing, digital readers, improved sensitivity, and next-generation molecular technologies, lateral flow assays are expected to remain an important component of the evolving global diagnostics landscape.

Explore our dedicated business services:

• Brainshare Consulting – End-to-end business consulting services including Opportunity assessment, GTM support, Competitive intelligence, and Consumer Analytics.

• Custom Research – Get a market intelligence report tailored to your specific requirements and aligned with your business goals.

• Consumer Insights – Capture real, evolving consumer sentiment and behavior to help you make data driven strategies.

• Horizon Databooks – Access the world’s largest portal of Market Reports & Statistics

• Investment Insights – Make investment decisions with data driven insights, powered by domain and technology

• Signal (Pricing Intelligence) - Commodity price intelligence to drives strategic advantage.

About us: 

Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.